Novel spectrophotometric methods for the determination of Leflunomide and Diacerein (cas 13739-02-1) in binary mixtures
-
Add time:09/09/2019 Source:sciencedirect.com
Two novel spectrophotometric methods were presented in this work using ethanol as a solvent. The first method was the ratio difference spectrophotometric method [RDSM], in which the amplitude difference between two selected wavelengths on the ratio spectra were recorded and used for estimation of each of Leflunomide LEF in mixture with its alkaline induced degradate DEG and also for Diacerein (cas 13739-02-1) DIA determination in mixture with Aceclofenac ACEC without interference from the other component in the mixture. The second method is the ratio subtraction coupled with constant multiplication [RS-CM], where LEF was determined in its mixture with its alkaline degradate DEG at 261 nm which is considered as a stability indicating assay. In addition to simultaneous determination of Diacerein DIA and Aceclofenac ACEC in their mixtures at 257 and 277 nm, respectively, by the second method without previous separation.Linearity was shown over the concentration range of [1.5-15 μg/ml] for LEF, [1-11 μg/ml] for DIA and [2.5-25 μg/ml] for ACEC, by both proposed methods. Leflunomide was found to be completely degraded when subjected to alkaline degradation producing one alkaline product. Validation of the suggested methods was conducted according to ICH guidelines, concerning precision, accuracy, repeatability. The suggested spectrophotometric methods were statistically compared to reference methods showing no significant difference. The suggested spectrophotometric methods are considered to be simple, sensitive and could be easily applied in quality control laboratories instead of LC methods.
We also recommend Trading Suppliers and Manufacturers of Diacerein (cas 13739-02-1). Pls Click Website Link as below: cas 13739-02-1 suppliers
Prev:Original articlePharmacokinetics and bioequivalence study of rhein as the main metabolite of Diacerein (cas 13739-02-1)
Next:Diacerein (cas 13739-02-1) protects against glycerol-induced acute kidney injury: Modulating oxidative stress, inflammation, apoptosis and necroptosis) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pharmacological treatment with Diacerein (cas 13739-02-1) combined with mechanical stimulation affects the expression of growth factors in human chondrocytes09/29/2019
- Formulation and optimization of niosomes for topical Diacerein (cas 13739-02-1) delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis09/28/2019
- Original articleDiacerein (cas 13739-02-1) orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial10/01/2019
- Original articleDiacerein (cas 13739-02-1) alleviates kidney injury through attenuating inflammation and oxidative stress in obese insulin-resistant rats09/27/2019
- Original ArticleValidated determination of Diacerein (cas 13739-02-1) and its active metabolite, rhein, by stability indicating constant pattern method as a novel manipulation of zero order spectra09/26/2019
- Diacerein (cas 13739-02-1) inhibits Estradiol-benzoate induced cervical hyperkeratosis in female rats09/25/2019
- Mechanical exposure and Diacerein (cas 13739-02-1) treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes09/24/2019
- Diacerein (cas 13739-02-1) protects against glycerol-induced acute kidney injury: Modulating oxidative stress, inflammation, apoptosis and necroptosis09/10/2019
- Original articlePharmacokinetics and bioequivalence study of rhein as the main metabolite of Diacerein (cas 13739-02-1)09/08/2019